In response to the Conservative Party’s manifesto promise, both industry and government have agreed to make production of new drugs to patients as attractive and innovation-embracing as possible. This, coupled with MHRA emerging from under the European Medicines Agency to function as a wholly independent body, presents an ongoing challenge.…